• English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • français 
    • English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • Ouvrir une session
Voir le document 
  •   Accueil de DSpace
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • Voir le document
  •   Accueil de DSpace
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • Voir le document
JavaScript is disabled for your browser. Some features of this site may not work without it.
Tout DSpace
  • Communautés & Collections
  • Par date de publication
  • Auteurs
  • Titres
  • Sujets

Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED

Thumbnail
Auteur
Sebastianelli A., Spatafora P., Morselli S., Vignozzi L., Serni S., McVary K.T., Kaplan S., Gravas S., Chapple C., Gacci M.
Date
2020
Language
en
DOI
10.1007/s11934-020-01009-7
Sujet
placebo
tadalafil
tamsulosin
tadalafil
tamsulosin
urinary tract agent
backache
bladder outlet obstruction index
Clinical Global Impression scale
combination drug therapy
dizziness
drug dose comparison
drug dose escalation
drug efficacy
drug safety
drug tolerability
drug withdrawal
dyspepsia
erectile dysfunction
headache
heartburn
human
hyperemia
hypotension
International Index of Erectile Function
International Prostate Symptom Score
lower urinary tract symptom
monotherapy
myalgia
nose obstruction
ocular hyperemia
postvoid residual urine volume
prostate hypertrophy
quality of life
Review
rhinopharyngitis
sexual satisfaction
side effect
systematic review
urine flow rate
complication
erectile dysfunction
lower urinary tract symptom
male
multimodality cancer therapy
randomized controlled trial (topic)
treatment outcome
Combined Modality Therapy
Erectile Dysfunction
Humans
Lower Urinary Tract Symptoms
Male
Prostatic Hyperplasia
Randomized Controlled Trials as Topic
Tadalafil
Tamsulosin
Treatment Outcome
Urological Agents
Springer
Afficher la notice complète
Résumé
Purpose of Review: Aim of our systematic review is to evaluate and summarize the efficacy and safety of tadalafil alone or in combination with tamsulosin for the management of lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). Recent Findings: Daily tadalafil, in particular 5 mg, according to retrieved studies, appears to be both safe and effective in treating LUTS/BPH and ED, compared with placebo or tamsulosin. The combination of daily tadalafil 5 mg and tamsulosin 0.4 mg allows a better improvement of LUTS compared with both the monotherapies, even if with an increased, but acceptable and tolerated, adverse events rate. After discontinuation of tamsulosin or tadalafil in patients previously treated with their combination, the improvement of LUTS retains significance compared with baseline. Summary: Tadalafil 5 mg should be considered a primary treatment option for patients with LUTS/BPH and ED. Evidence highlight an excellent tolerability, safety, and effectiveness profile, both alone or in combination with tamsulosin 0.4 mg. A better efficacy on LUTS relief has been observed for combination therapy, preserving also sexual function. The further switch to monotherapy allows to preserve LUTS relief, but tadalafil only is able to retain ED improvement. Our results support the evidence for a more and more tailored and modular LUTS treatment. © 2020, The Author(s).
URI
http://hdl.handle.net/11615/78876
Collections
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ. [19735]
htmlmap 

 

Parcourir

Tout DSpaceCommunautés & CollectionsPar date de publicationAuteursTitresSujetsCette collectionPar date de publicationAuteursTitresSujets

Mon compte

Ouvrir une sessionS'inscrire
Help Contact
DepositionAboutHelpContactez-nous
Choose LanguageTout DSpace
EnglishΕλληνικά
htmlmap